Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark D Minden

Showing results (151-160 of 308) with videos related to

Pageof 31
Sort By:
Cancer|February 13, 2025
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 studyEmmanuel Gyan, Mark D Minden, Kohmei Kubo, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Multi-platform reassessment of human mitochondrial DNA methylation reveals signals consistent with technical artifactsSalman Basrai, Alexander T Bahcheli, Djarren Tan, et al.
Molecular Cancer Therapeutics|November 13, 2008
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell deathTabitha E Wood, Shadi Dalili, Craig D Simpson, et al.
Cell Death & Disease|December 23, 2016
Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2Zhuo Ren, Joeri L Aerts, Hugo Vandenplas, et al.
Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Nature Communications|April 29, 2021
Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joiningTzah Feldman, Akhiad Bercovich, Yoni Moskovitz, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 31, 2025
Identifying Risk Factors and Outcome for CNS Involvement in AMLJack T Seki, Georgina S Daher-Reyes, Eshetu G Atenafu, et al.
American Journal of Hematology|December 1, 2015
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapyUday Deotare, Karen W L Yee, Lisa W Le, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemiaFrancesca Lovat, Giovanni Nigita, Rosario Distefano, et al.
Experimental Hematology|October 24, 2018
Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expressionGenna M Luciani, Lihua Xie, David Dilworth, et al.
Pageof 31

Showing results (151-160 of 308) with videos related to

Sort By:
Pageof 31
Cancer|February 13, 2025
Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in patients with FMS-like tyrosine kinase 3-internal tandem duplication acute myeloid leukemia: A phase 2 studyEmmanuel Gyan, Mark D Minden, Kohmei Kubo, et al.
Biorxiv : the Preprint Server for Biology|June 29, 2026
Multi-platform reassessment of human mitochondrial DNA methylation reveals signals consistent with technical artifactsSalman Basrai, Alexander T Bahcheli, Djarren Tan, et al.
Molecular Cancer Therapeutics|November 13, 2008
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell deathTabitha E Wood, Shadi Dalili, Craig D Simpson, et al.
Cell Death & Disease|December 23, 2016
Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2Zhuo Ren, Joeri L Aerts, Hugo Vandenplas, et al.
Leukemia Research|August 22, 2016
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)Farhad Ravandi, Ivana Gojo, Mrinal M Patnaik, et al.
Nature Communications|April 29, 2021
Recurrent deletions in clonal hematopoiesis are driven by microhomology-mediated end joiningTzah Feldman, Akhiad Bercovich, Yoni Moskovitz, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 31, 2025
Identifying Risk Factors and Outcome for CNS Involvement in AMLJack T Seki, Georgina S Daher-Reyes, Eshetu G Atenafu, et al.
American Journal of Hematology|December 1, 2015
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-Color flow cytometry diagnosis and HyperCVAD therapyUday Deotare, Karen W L Yee, Lisa W Le, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 20, 2020
Combined loss of function of two different loci of miR-15/16 drives the pathogenesis of acute myeloid leukemiaFrancesca Lovat, Giovanni Nigita, Rosario Distefano, et al.
Experimental Hematology|October 24, 2018
Characterization of inv(3) cell line OCI-AML-20 with stroma-dependent CD34 expressionGenna M Luciani, Lihua Xie, David Dilworth, et al.
Pageof 31